Original Article

You have free access to this content

Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers

  1. Karen Chiam1,†,
  2. Natalie K. Ryan1,
  3. Carmela Ricciardelli2,
  4. Tanya K. Day1,
  5. Grant Buchanan3,
  6. Aleksandra M. Ochnik1,
  7. Krisna Murti1,‡,
  8. Luke A. Selth1,
  9. Australian Prostate Cancer BioResource4,
  10. Lisa M. Butler1,
  11. Wayne D. Tilley1,
  12. Tina Bianco-Miotto1,*

Article first published online: 10 JUL 2012

DOI: 10.1002/pros.22554

Issue

The Prostate

The Prostate

Volume 73, Issue 2, pages 182–193, January 2013

Additional Information

How to Cite

Chiam, K., Ryan, N. K., Ricciardelli, C., Day, T. K., Buchanan, G., Ochnik, A. M., Murti, K., Selth, L. A., Australian Prostate Cancer BioResource, Butler, L. M., Tilley, W. D. and Bianco-Miotto, T. (2013), Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73: 182–193. doi: 10.1002/pros.22554

Author Information

  1. 1

    Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, Discipline of Medicine, The University of Adelaide and Hanson Institute, Adelaide, Australia

  2. 2

    Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, The Robinson Institute, The University of Adelaide, South Australia, Australia

  3. 3

    The Freemasons Foundation Centre for Men's Health, Basil Hetzel Institute for Translational Health Research, The University of Adelaide, South Australia, Australia

  4. 4

    Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia

  1. †

    Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.

  2. ‡

    Department of Pathology, Faculty of Medicine, Sriwijaya University, Sumatra, Indonesia.

*The Robinson Institute, Research Centre for Reproductive Health & Early Origins of Health and Disease, School of Paediatrics and Reproductive Health, The University of Adelaide, South Australia 5005, Australia.

Publication History

  1. Issue published online: 24 DEC 2012
  2. Article first published online: 10 JUL 2012
  3. Manuscript Accepted: 5 JUN 2012
  4. Manuscript Received: 23 FEB 2012

Funded by

  • National Health and Medical Research Council. Grant Number: 627185
  • The Australian Prostate Cancer BioResource by the National Health and Medical Research Council of Australia. Grant Numbers: 290456, 614296
  • Prostate Cancer Foundation of Australia. Grant Numbers: ID 2011/0452, YI02, YIG03, YI0810, PG2210, EG0809
  • The Cancer Institute NSW Translational Program Grant
  • The Hilda Farmer Research Fellowship (University of Adelaide Medical Endowment Funds)
  • Cancer Council of South Australia Senior Research Fellowship
  • W Bruce Hall Cancer Council of South Australia Research Fellowship
  • United States Department of Defense Prostate Cancer Research Program Training Fellowship

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (403K)

REFERENCES

  • 1
    Bieker JJ. Kruppel-like factors: Three fingers in many pies. J Biol Chem 2001; 276(37): 34355–34358.
  • 2
    Pearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Kruppel-like transcription factors: A functional family. Int J Biochem Cell Biol 2008; 40(10): 1996–2001.
  • 3
    DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12(1–2): 1–7.
  • 4
    Narla G, Friedman SL, Martignetti JA. Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 2003; 162(4): 1047–1052.
  • 5
    Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005; 65(13): 5761–5768.
  • 6
    Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D, Friedman SL. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004; 64(11): 3885–3891.
  • 7
    Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, Katz A, Isaacs WB, Hebbring S, Komiya A, McDonnell SK, Wiley KE, Jacobsen SJ, Isaacs SD, Walsh PC, Zheng SL, Chang BL, Friedrichsen DM, Stanford JL, Ostrander EA, Chinnaiyan AM, Rubin MA, Xu J, Thibodeau SN, Friedman SL, Martignetti JA. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65(4): 1213–1222.
  • 8
    Cheng XF, Li D, Zhuang M, Chen ZY, Lu DX, Hattori T. Growth inhibitory effect of Kruppel-like factor 6 on human prostatic carcinoma and renal carcinoma cell lines. Tohoku J Exp Med 2008; 216(1): 35–45.
  • 9
    Huang X, Li X, Guo B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 2008; 283(44): 29795–29801.
  • 10
    Leow CC, Wang BE, Ross J, Chan SM, Zha J, Carano RA, Frantz G, Shen MM, de Sauvage FJ, Gao WQ. Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway. J Biol Chem 2009; 284(31): 21057–21065.
  • 11
    Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294(5551): 2563–2566.
  • 12
    Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008; 118(8): 2711–2721.
  • 13
    Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF Jr, Vessella RL, Dong JT. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003; 162(4): 1349–1354.
  • 14
    Hermans KG, van Alewijk DC, Veltman JA, van Weerden W, van Kessel AG, Trapman J. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes Cancer 2004; 39(3): 171–184.
    Direct Link:
  • 15
    Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113(6): 913–923.
  • 16
    Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66(5): 2815–2825.
  • 17
    Yin D, Komatsu N, Miller CW, Chumakov AM, Marschesky A, McKenna R, Black KL, Koeffler HP. KLF6: Mutational analysis and effect on cancer cell proliferation. Int J Oncol 2007; 30(1): 65–72.
  • 18
    Cho YG, Choi BJ, Song JW, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS. Aberrant expression of krUppel-like factor 6 protein in colorectal cancers. World J Gastroenterol 2006; 12(14): 2250–2253.
  • 19
    Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K, Sekido Y. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res 2004; 64(11): 3838–3843.
  • 20
    Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer 2009; 45(4): 666–676.
  • 21
    Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer 2007; 121(6): 1390–1395.
    Direct Link:
  • 22
    Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, Nunez Rodriguez N, Liang BC, Guha A, Martignetti JA, Friedman SL, Chan AM. Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6. Oncogene 2004; 23(29): 5077–5083.
  • 23
    Hartel M, Narla G, Wente MN, Giese NA, Martignoni ME, Martignetti JA, Friess H, Friedman SL. Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur J Cancer 2008; 44(13): 1895–1903.
  • 24
    Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuutila S, Wikman H. Differentially expressed genes in nonsmall cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004; 149(2): 98–106.
  • 25
    DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res 2006; 12(12): 3730–3739.
  • 26
    Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Kruppel-like factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer. J Urol 2004; 172(2): 506–507.
  • 27
    Lievre A, Landi B, Cote JF, Veyrie N, Zucman-Rossi J, Berger A, Laurent-Puig P. Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene 2005; 24(48): 7253–7256.
  • 28
    Boyault S, Herault A, Balabaud C, Zucman-Rossi J. Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology 2005; 41(3): 681–682 author reply 682–683.
    Direct Link:
  • 29
    Bar-Shira A, Matarasso N, Rosner S, Bercovich D, Matzkin H, Orr-Urtreger A. Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6. Prostate 2006; 66(10): 1052–1060.
    Direct Link:
  • 30
    Agell L, Hernandez S, de Muga S, Lorente JA, Juanpere N, Esgueva R, Serrano S, Gelabert A, Lloreta J. KLF6 and TP53 mutations are a rare event in prostate cancer: Distinguishing between Taq polymerase artifacts and true mutations. Mod Pathol 2008; 21(12): 1470–1478.
  • 31
    Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2(6): 485–495.
  • 32
    Hirasawa Y, Arai M, Imazeki F, Tada M, Mikata R, Fukai K, Miyazaki M, Ochiai T, Saisho H, Yokosuka O. Methylation status of genes upregulated by demethylating agent 5-aza-2'-deoxycytidine in hepatocellular carcinoma. Oncology 2006; 71(1–2): 77–85.
  • 33
    Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56(18): 4096–4102.
  • 34
    Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 2010; 19(10): 2611–2622.
  • 35
    Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164(1): 217–227.
  • 36
    Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W, Michalopoulos G, Becich M, Monzon FA. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
  • 37
    Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18(1): 11–22.
  • 38
    Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL, Coetzee GA, Tilley WD. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Res 2007; 67(20): 10087–10096.
  • 39
    Tan LW, Bianco T, Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis 2002; 23(2): 231–236.
  • 40
    Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, Marshall VR, Horsfall DJ, Tilley WD. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 2005; 63(1): 19–28.
    Direct Link:
  • 41
    Ricciardelli C, Jackson MW, Choong CS, Stahl J, Marshall VR, Horsfall DJ, Tilley WD. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 2008; 68(8): 830–838.
    Direct Link:
  • 42
    Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: Measurement by color video image analysis. Cancer Res 1994; 54(15): 4096–4102.
  • 43
    Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS ONE 2011; 6(9): e25634.
  • 44
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93(18): 9821–9826.
  • 45
    Song J, Kim CJ, Cho YG, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY, Park WS. Genetic and epigenetic alterations of the KLF6 gene in hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21(8): 1286–1289.
    Direct Link:
  • 46
    Seppala EH, Autio V, Duggal P, Ikonen T, Stenman UH, Auvinen A, Bailey-Wilson JE, Tammela TL, Schleutker J. KLF6 IVS1-27G>A variant and the risk of prostate cancer in Finland. Eur Urol 2007; 52(4): 1076–1081.
  • 47
    Muhlbauer KR, Grone HJ, Ernst T, Grone E, Tschada R, Hergenhahn M, Hollstein M. Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer 2003; 89(4): 687–690.
  • 48
    Gehrau RC, D'Astolfo DS, Prieto C, Bocco JL, Koritschoner NP. Genomic organization and functional analysis of the gene encoding the Kruppel-like transcription factor KLF6. Biochim Biophys Acta 2005; 1730(2): 137–146.
  • 49
    Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q, Chen CS. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem 2011; 286(12), 9968–9976.
View Full Article with Supporting Information (HTML) Get PDF (403K)